Palmetto GBA Medicare Coverage Update for NanoKnife IRE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Medicare Coverage Update: Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) effective July 5, 2026, providing Medicare coverage for irreversible electroporation (IRE) technology, marking a significant advancement for AngioDynamics' NanoKnife system in treating prostate and liver cancers.
- CPT Code Activation: The American Medical Association activated Category I CPT codes for IRE procedures on January 1, 2026, indicating clinical effectiveness and widespread adoption, thereby supporting standardized billing across hospital outpatient departments and ambulatory surgical centers.
- Patient Selection Criteria: Under the LCD, IRE is covered for appropriately selected patients with favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver, ensuring enhanced access to treatment options and improving patient care.
- Alignment with Clinical Guidelines: The LCD aligns with clinical practice guidelines from major specialty societies, reinforcing IRE's recognition as an effective treatment option and enhancing AngioDynamics' competitive position in the healthcare market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANGO
Wall Street analysts forecast ANGO stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.790
Low
16.00
Averages
19.33
High
24.00
Current: 11.790
Low
16.00
Averages
19.33
High
24.00
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palmetto GBA Medicare Coverage Update for NanoKnife IRE
- Medicare Coverage Update: Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) effective July 5, 2026, providing Medicare coverage for irreversible electroporation (IRE) technology, marking a significant advancement for AngioDynamics' NanoKnife system in treating prostate and liver cancers.
- CPT Code Activation: The American Medical Association activated Category I CPT codes for IRE procedures on January 1, 2026, indicating clinical effectiveness and widespread adoption, thereby supporting standardized billing across hospital outpatient departments and ambulatory surgical centers.
- Patient Selection Criteria: Under the LCD, IRE is covered for appropriately selected patients with favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver, ensuring enhanced access to treatment options and improving patient care.
- Alignment with Clinical Guidelines: The LCD aligns with clinical practice guidelines from major specialty societies, reinforcing IRE's recognition as an effective treatment option and enhancing AngioDynamics' competitive position in the healthcare market.
See More
AngioDynamics Reports Strong Revenue Growth in Med Tech Segment
- Significant Revenue Growth: AngioDynamics reported an 8.9% increase in total revenue to $78.4 million, with the Med Tech segment achieving $37.3 million in revenue, reflecting a robust 19% growth that underscores the company's strong performance and rising market demand.
- Auryon Platform's Continued Strength: The Auryon platform achieved its 19th consecutive quarter of double-digit year-over-year growth, generating $16.3 million in revenue, indicating its competitive position and technological superiority, which are expected to further drive the company's future growth.
- Optimistic Financial Outlook: The company raised its full-year revenue guidance to $313.5 million to $315.5 million, while also increasing adjusted EBITDA guidance to $10 million to $12 million, reflecting management's confidence in future performance.
- Gross Margin Decline Challenges: Despite revenue growth, gross margin decreased by 110 basis points year-over-year, primarily due to tariffs and inflation, with tariff expenses expected to range between $4 million and $6 million for fiscal year 2026, potentially impacting the company's profitability.
See More
AngioDynamics Reports Strong Q3 FY2026 Earnings Growth
- Significant Revenue Growth: AngioDynamics reported Q3 revenue of $78.4 million, an 8.9% increase year-over-year, surpassing analyst estimates of $76.766 million, which enhances market confidence in the company's performance.
- Strong Med Tech Performance: The Med Tech segment generated $37.3 million in revenue, up 19% and accounting for 48% of total revenue, reflecting a continued shift in business mix that is expected to drive future profitability and market share growth.
- Auryon Momentum: Auryon achieved its 19th consecutive quarter of double-digit year-over-year growth, supported by expansion into the hospital market and CE Mark approval, indicating strengthening competitive positioning in the medical device sector.
- Optimistic Outlook: The company raised its FY2026 net sales guidance to $313.5 million to $315.5 million and adjusted EBITDA guidance to $10 million to $12 million, demonstrating management's confidence in future performance and positive market expectations.
See More
AngioDynamics Reports Wider Loss in Q3 Earnings
- Loss Report: AngioDynamics reported a GAAP net loss of $8.1 million in Q3, translating to a loss per share of $0.19, which is a significant increase from last year's loss of $4.4 million or $0.11 per share, indicating worsening financial health.
- Adjusted Financials: On a pro forma basis, the net loss was $13.1 million or $0.31 per share, compared to a loss of $9.9 million or $0.24 per share last year, reflecting ongoing operational challenges faced by the company.
- Sales Growth: The company achieved net sales of $78.4 million in Q3, an 8.9% increase year-over-year, with Med Tech sales rising to $37.3 million, a 19.0% increase from $31.3 million last year, demonstrating strong market demand.
- Revised Outlook: For fiscal 2026, the adjusted loss per share is now expected to be in the range of $0.30 to $0.23, revised from a previous guidance of $0.33 to $0.23, while adjusted EBITDA expectations have been raised to $10.0 to $12.0 million, indicating cautious optimism about future performance.
See More
AngioDynamics Reports Sixth Consecutive Quarter of Double-Digit Growth
- Performance Highlights: AngioDynamics reported net sales of $78.4 million for Q3 FY 2026, an 8.9% year-over-year increase, with the Med Tech segment achieving $37.3 million in sales, reflecting a robust 19.0% growth that underscores the company's strong position in the medical technology sector.
- Adjusted EBITDA: The company recorded an adjusted EBITDA of $1.8 million in Q3, up 38.5% from $1.3 million in the prior year, indicating ongoing improvements in operational efficiency and cost management, which bolster confidence in future profitability.
- Cash Flow Status: As of February 28, 2026, AngioDynamics maintained a cash balance of $37.8 million and a debt-free status, demonstrating strong financial management and providing ample resources for future investments and expansion.
- Future Outlook: The company raised its guidance for FY 2026, now expecting net sales between $313.5 million and $315.5 million and adjusted EBITDA of $10 million to $12 million, reflecting management's confidence in sustained growth moving forward.
See More
AngioDynamics Q3 Earnings Exceed Expectations
- Earnings Beat: AngioDynamics reported a Q3 non-GAAP EPS of -$0.07, beating expectations by $0.04, indicating improved profitability and boosting market confidence in future performance.
- Revenue Growth: The company achieved revenue of $78.42 million in Q3, an 8.9% year-over-year increase that surpassed market expectations by $1.65 million, demonstrating strong demand for its products, particularly in the Med Tech sector.
- Strong Med Tech Sales: Med Tech net sales reached $37.3 million, a 19% increase from $31.3 million in the prior-year period, showcasing significant growth in market share and competitiveness in this segment.
- Guidance Upgrade for FY 2026: AngioDynamics raised its FY 2026 net sales guidance to $314 million, up from the previous range of $312 million to $314 million, reflecting a positive outlook for future growth.
See More
Palmetto GBA Medicare Coverage Update for NanoKnife IRE
- Medicare Coverage Update: Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) effective July 5, 2026, providing Medicare coverage for irreversible electroporation (IRE) technology, marking a significant advancement for AngioDynamics' NanoKnife system in treating prostate and liver cancers.
- CPT Code Activation: The American Medical Association activated Category I CPT codes for IRE procedures on January 1, 2026, indicating clinical effectiveness and widespread adoption, thereby supporting standardized billing across hospital outpatient departments and ambulatory surgical centers.
- Patient Selection Criteria: Under the LCD, IRE is covered for appropriately selected patients with favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver, ensuring enhanced access to treatment options and improving patient care.
- Alignment with Clinical Guidelines: The LCD aligns with clinical practice guidelines from major specialty societies, reinforcing IRE's recognition as an effective treatment option and enhancing AngioDynamics' competitive position in the healthcare market.
See More
AngioDynamics Reports Strong Revenue Growth in Med Tech Segment
- Significant Revenue Growth: AngioDynamics reported an 8.9% increase in total revenue to $78.4 million, with the Med Tech segment achieving $37.3 million in revenue, reflecting a robust 19% growth that underscores the company's strong performance and rising market demand.
- Auryon Platform's Continued Strength: The Auryon platform achieved its 19th consecutive quarter of double-digit year-over-year growth, generating $16.3 million in revenue, indicating its competitive position and technological superiority, which are expected to further drive the company's future growth.
- Optimistic Financial Outlook: The company raised its full-year revenue guidance to $313.5 million to $315.5 million, while also increasing adjusted EBITDA guidance to $10 million to $12 million, reflecting management's confidence in future performance.
- Gross Margin Decline Challenges: Despite revenue growth, gross margin decreased by 110 basis points year-over-year, primarily due to tariffs and inflation, with tariff expenses expected to range between $4 million and $6 million for fiscal year 2026, potentially impacting the company's profitability.
See More
AngioDynamics Reports Strong Q3 FY2026 Earnings Growth
- Significant Revenue Growth: AngioDynamics reported Q3 revenue of $78.4 million, an 8.9% increase year-over-year, surpassing analyst estimates of $76.766 million, which enhances market confidence in the company's performance.
- Strong Med Tech Performance: The Med Tech segment generated $37.3 million in revenue, up 19% and accounting for 48% of total revenue, reflecting a continued shift in business mix that is expected to drive future profitability and market share growth.
- Auryon Momentum: Auryon achieved its 19th consecutive quarter of double-digit year-over-year growth, supported by expansion into the hospital market and CE Mark approval, indicating strengthening competitive positioning in the medical device sector.
- Optimistic Outlook: The company raised its FY2026 net sales guidance to $313.5 million to $315.5 million and adjusted EBITDA guidance to $10 million to $12 million, demonstrating management's confidence in future performance and positive market expectations.
See More
AngioDynamics Reports Wider Loss in Q3 Earnings
- Loss Report: AngioDynamics reported a GAAP net loss of $8.1 million in Q3, translating to a loss per share of $0.19, which is a significant increase from last year's loss of $4.4 million or $0.11 per share, indicating worsening financial health.
- Adjusted Financials: On a pro forma basis, the net loss was $13.1 million or $0.31 per share, compared to a loss of $9.9 million or $0.24 per share last year, reflecting ongoing operational challenges faced by the company.
- Sales Growth: The company achieved net sales of $78.4 million in Q3, an 8.9% increase year-over-year, with Med Tech sales rising to $37.3 million, a 19.0% increase from $31.3 million last year, demonstrating strong market demand.
- Revised Outlook: For fiscal 2026, the adjusted loss per share is now expected to be in the range of $0.30 to $0.23, revised from a previous guidance of $0.33 to $0.23, while adjusted EBITDA expectations have been raised to $10.0 to $12.0 million, indicating cautious optimism about future performance.
See More
AngioDynamics Reports Sixth Consecutive Quarter of Double-Digit Growth
- Performance Highlights: AngioDynamics reported net sales of $78.4 million for Q3 FY 2026, an 8.9% year-over-year increase, with the Med Tech segment achieving $37.3 million in sales, reflecting a robust 19.0% growth that underscores the company's strong position in the medical technology sector.
- Adjusted EBITDA: The company recorded an adjusted EBITDA of $1.8 million in Q3, up 38.5% from $1.3 million in the prior year, indicating ongoing improvements in operational efficiency and cost management, which bolster confidence in future profitability.
- Cash Flow Status: As of February 28, 2026, AngioDynamics maintained a cash balance of $37.8 million and a debt-free status, demonstrating strong financial management and providing ample resources for future investments and expansion.
- Future Outlook: The company raised its guidance for FY 2026, now expecting net sales between $313.5 million and $315.5 million and adjusted EBITDA of $10 million to $12 million, reflecting management's confidence in sustained growth moving forward.
See More
AngioDynamics Q3 Earnings Exceed Expectations
- Earnings Beat: AngioDynamics reported a Q3 non-GAAP EPS of -$0.07, beating expectations by $0.04, indicating improved profitability and boosting market confidence in future performance.
- Revenue Growth: The company achieved revenue of $78.42 million in Q3, an 8.9% year-over-year increase that surpassed market expectations by $1.65 million, demonstrating strong demand for its products, particularly in the Med Tech sector.
- Strong Med Tech Sales: Med Tech net sales reached $37.3 million, a 19% increase from $31.3 million in the prior-year period, showcasing significant growth in market share and competitiveness in this segment.
- Guidance Upgrade for FY 2026: AngioDynamics raised its FY 2026 net sales guidance to $314 million, up from the previous range of $312 million to $314 million, reflecting a positive outlook for future growth.
See More
